U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07185932) titled 'Efficacy and Safety of Rifaximin in Treating MAFLD' on Aug. 21.
Brief Summary: Study Objective: to evaluate the efficacy and safety of rifaximin in the treatment of metabolic-associated fatty liver disease (MAFLD), and investigate the underlying mechanisms by which rifaximin influence MAFLD progression.
Target Population: patients diagnosed with MAFLD. Intervention: this single-center, single-arm exploratory study will enroll up to 40 eligible MAFLD patients who meet the inclusion criteria, do not meet any exclusion criteria, and provide written informed consent. Participants will receive oral rifaximin at a dosage of 1200 mg/day ...